Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | VNN1 | O95497 | 8/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209589 | 0.85 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC6SYK | |
| SCHEMBL2733463 | 0.77 | HDAC1 (0.59) | HDAC1HDAC3HDAC2HDAC6VCP | |
| SCHEMBL14822487 | 0.73 | P4HA1 (0.53) | — | |
| SCHEMBL27717831 | 0.73 | VNN1 (0.59) | HDAC1VNN1HDAC3HDAC2HDAC6 | |
| SCHEMBL600427 | 0.72 | P4HA1 (0.52) | — | |
| SCHEMBL16397614 | 0.71 | KMT2A (0.60) | HDAC1VNN1HDAC3HDAC2HDAC6 | |
| SCHEMBL2732645 | 0.67 | KMT2A (0.59) | EPHX2NR1H4SMN1; SMN2KMT2A | |
| SCHEMBL16408476 | 0.67 | VCP (0.59) | HDAC1VNN1HDAC3HDAC2HDAC6 | |
| SCHEMBL946562 | 0.67 | KMO (0.51) | HDAC1SYKSMN1; SMN2 | |
| SCHEMBL2340910 | 0.67 | RXRA (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885VNN1 2936/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.